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Letters to the Editor786tenosis. Two years later, ISR developed that was treated with
nother SES. Once again, re-ISR developed 19 months later inside
he SES that was implanted for ISR of the initial SES. Multimo-
ality imaging (intravascular ultrasound [IVUS], coronary angios-
opy, and optical coherence tomography [OCT]) were used (Fig.
). IVUS showed the culprit lesion, which was an ISR lesion, to
e echolucent tissue. Coronary angioscopy showed it to be
harply demarcated white tissue. OCT findings of the lesion
howed that although the surface of the culprit lesion (which
ppeared as a white surface by angioscopy) was a signal-rich
tructure, underneath it contained a low signal and some
icrochannels in the deeper layer tissue. Percutaneous coronary
ntervention was performed with a distal protection device, and
he pathological examination of the aspirate demonstrated fibrin
lots (Fig. 2). Kume et al. (1) reported earlier that signal-rich
tructures without backscattering visualized by OCT are fibrin
lots. The low-signal images in the deep tissue layer contained
icrochannels suggestive of organized thrombi. These results
ndicate that the white neointima-like coverage visualized by
ngioscopy after SES implantation could be a fibrin clot covering
hronically formed thrombi, and that multimodality imaging
ould help in understanding the pathogenesis of ISR patterns
fter drug-eluting stent implantation.
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Figure 2. Pathological Findings Collected From the Culprit Lesion Showed
(A) Hematoxylin and eosin stain. (B) Phosphotungstic acid hematoxylin stain.or supplementary videos and their legends, please see the online version of this
rticle.
1at Around the Heart
e are intrigued by the report of Cheng et al. (1) on pericardial fat
olume as a predictor of increased death and disability for cardio-
ascular disease. Although the investigators were not able to
istinguish epicardial fat from pericardial fat and consequently
mitted a discussion on the prognostic value of epicardial fat in
redicting premature death and disability from cardiovascular
isease, the data are of great interest. Threshold values of epicardial
at thickness (measured by echocardiography) were established
reviously, and increased epicardial fat mass was proposed as a
redictor of cardiovascular disease by Iacobellis et al. (2). Further-
ore, current knowledge of epicardial and pericardial fat suggests
hat these 2 tissues have different metabolic and physiologic
roperties (3–5). Given the difference in the metabolic function and
natomical locations of epicardial and pericardial fat, it may be
easonable to ask the following 2 questions. First, does pericardial
at increase the atherosclerotic burden because of the known
mmunomodulatory function of white adipose tissue (6,7)? Sec-
ndly, does epicardial fat increase the chances of heart failure
ecause of its anatomical proximity to the myocardium? We have
easoned previously that epicardial fat delivers substrate directly to
he heart and sets the stage for myocardial steatosis, akin to visceral
at setting the stage for hepatic steatosis (8). In short, there remain
any unanswered questions regarding the fat around the heart, but
ith the help of modern technologies, the answers may be just
round the corner.
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in ClotsFibr. Cheng VY, Dey D, Tamarappoo B, et al. Pericardial fat burden on
ECG-gated noncontrast CT in asymptomatic patients who subsequently
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e appreciate the letter from Thomas et al. for emphasizing the
merging value of measuring fat around the heart. However, we
espectfully disagree with the primary assertion in the letter, since
e in fact did study epicardial fat as defined by the letter authors.
n computed tomography (CT), our designation of pericardial fat
as “all adipose tissue detected within the pericardium,” which
atches the definition of epicardial fat specified by Iacobellis et al.
1). A closer look at our work will additionally reveal that we
eparately studied the volume of adipose tissue inside and outside of
he pericardium. In doing so, we showed that only fat inside the
ericardium held predictive power for the risk of future cardiovas-
ular events.
Although some investigators performing CT-based research
ave defined pericardial fat as we did (2–4), others have used
ericardial fat to encompass adipose tissue both inside and outside
f the pericardium (5,6). Undoubtedly this nonuniform labeling
reates confusion. Given the increasing attention paid to fat
urrounding the heart and coronary arteries, standardization of
erminology may be in order. This notwithstanding, readers of the
iterature should cautiously examine the methodology to ensure
nderstanding of the exact fatty depot being measured.
The ability to derive additional prognostic information from stan-
ard noncontrast calcium scoring CT by quantifying fat volume inside
he pericardium is important. We look forward to understanding
urther the impact of this measure through future investigations.
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rognostic Signiﬁcance of
train Imaging in Amyloidosis
n the interesting article in a recent issue of iJACC by Koyama et al.
1), tissue Doppler (TD) longitudinal strain measured at the left
entricular (LV) base was reported to be an independent predictor
f outcome in patients with cardiac amyloid light-chain (AL)
myloidosis. These findings point out an interesting potential
linical application of strain imaging for risk stratification in these
ubjects. However, caution is needed in accepting the independent
rognostic role of basal strain, as a number of established prognostic
actors, such as LV ejection fraction, New York Heart Association
unctional class, natriuretic peptide plasma concentration, cardiac
roponins, indexed left atrial volume, the ratio of mitral peak
elocity of early filling to early diastolic mitral annular velocity, right
entricular dysfunction, and renal failure, were not considered in
urvival analyses. Several evidences confirmed a major impact of
hese factors on clinical outcome in patients with cardiac AL
myloidosis (2). This may be of particular importance because
early 70% of cardiovascular events (15 of 22) occurred in group 3
cardiac amyloidosis with clinical evidence of heart failure), where
he relative contribution of these variables to clinical outcome is
xpected to be relevant. Even if a subgroup analysis showed a
orderline significant association of basal strain with outcome
mong patients with no clinical evidence of heart failure, it should
e considered that most of these variables are important deter-
inants of outcome in the pre-clinical stages of heart failure as
ell (3).
In addition, we believe that the evaluation of strain imaging as a
rognosticator in cardiac AL amyloidosis should not be limited to
he assessment of baseline deformation values. We recently reported
n early improvement in both average longitudinal strain and
ystolic dyssynchrony after treatment with melphalan and dexa-
ethasone, an aspect that was not detectable by color TD (4).
ecause response to therapy is an important predictor of survival in
hese patients, the prognostic meaning of changes in strain pattern
fter therapy might be an intriguing issue to investigate. The clinical
mpact of myocardial dyssynchrony—a controversial question in car-
iac amyloidosis, for which, to date, 3-dimensional echocardiography
nd color TD have yielded conflicting results, ranging from increased
yssynchrony to abnormal hypersynchronization—may also represent
n interesting application of strain imaging. Lastly, the promising role
f speckle tracking imaging should be pointed out. Very recent
